OverviewSuggest Edit

Theravance Biopharma is a biopharmaceutical company which provides medicines to treat serious illnesses. It focuses on several therapeutic areas, including infectious disease, respiratory, gastrointestinal disease, and cardiovascular and renal disease.
TypePublic
Founded1996
HQDublin, IE
Websitetheravance.com
Overall CultureB-

Latest Updates

Employees (est.) (Mar 2019)363(+7%)
Revenue (FY, 2018)$60.4 M(+293%)
Share Price (Jan 2021)$17.7 (+4%)
Cybersecurity ratingAMore

Key People/Management at Theravance Biopharma

Rick Winningham

Rick Winningham

CEO
Gary Barrera

Gary Barrera

Vice President
Eran Broshy

Eran Broshy

Director
Dennis O. Driver

Dennis O. Driver

Senior Vice President, Human Resources, Organizational and Leadership Development
Reigin Zawadzki

Reigin Zawadzki

Vice President, Human Resources
Robert V. Gunderson

Robert V. Gunderson

Director
Show more

Theravance Biopharma Office Locations

Theravance Biopharma has offices in Dublin and San Francisco
Dublin, IE (HQ)
Connaught House, 1 Burlington Rd
San Francisco, CA, US
901 Gateway Boulevard
Show all (2)

Theravance Biopharma Financials and Metrics

Theravance Biopharma Revenue

Embed Graph
View revenue for all periods
Theravance Biopharma's revenue was reported to be $60.37 m in FY, 2018 which is a 292.4% increase from the previous period.
USD

Revenue (FY, 2018)

60.4m

Revenue growth (FY, 2017 - FY, 2018), %

292.4%

Gross profit (FY, 2018)

59.7m

Gross profit margin (FY, 2018), %

98.8%

Net income (FY, 2018)

(215.5m)

EBIT (FY, 2018)

(238.8m)

Market capitalization (8-Jan-2021)

1.1b

Closing stock price (8-Jan-2021)

17.7

Cash (31-Dec-2018)

378.0m

EV

976.7m
Theravance Biopharma's current market capitalization is $1.1 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

48.6m15.4m60.4m

Revenue growth, %

(68%)292%

Cost of goods sold

2.9m6.0m715.0k

Gross profit

45.8m9.4m59.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

18.4m5.5m19.1m3.1m3.5m4.3m8.3m23.5m12.8m

Cost of goods sold

778.0k638.0k332.0k565.0k1.4m985.0k1.4m705.0k

Gross profit

17.6m4.8m18.7m2.5m2.1m3.3m22.0m12.1m

Gross profit Margin, %

96%88%98%82%61%77%94%95%
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

344.7m89.0m378.0m

Accounts Receivable

646.0k2.3m620.0k

Inventories

12.2m16.8m

Current Assets

528.5m378.7m532.8m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

128.8m148.4m86.6m169.9m139.6m91.3m125.8m103.9m101.2m

Accounts Receivable

1.5m1.9m873.0k1.2m1.3m1.6m2.0m3.4m3.0m

Inventories

9.4m9.8m12.5m13.2m12.1m15.3m17.2m17.9m17.9m

Current Assets

238.8m303.1m274.0m421.5m384.9m367.1m446.8m386.7m332.6m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(190.7m)(285.4m)(215.5m)

Depreciation and Amortization

3.1m4.0m3.2m

Inventories

(3.2m)(7.3m)(1.6m)

Accounts Payable

(16.4m)3.8m3.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(42.1m)(89.4m)(123.3m)(65.3m)(131.6m)(198.5m)(65.1m)(105.9m)(165.3m)

Depreciation and Amortization

699.0k1.2m1.9m1.1m2.1m3.0m900.0k1.7m2.3m

Inventories

134.0k157.0k(1.8m)140.0k(497.0k)(3.0m)(371.0k)(351.0k)(552.0k)

Accounts Payable

(9.4m)(10.8m)(12.8m)2.0m4.8m3.5m(449.0k)(2.3m)(1.7m)
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Theravance Biopharma Operating Metrics

FY, 2016FY, 2017FY, 2018Apr, 2019

Partners

6

Patents (Foreign)

1.68 k1.96 k1.67 k

Patents (US)

434 459 438
Show all operating metrics

Theravance Biopharma Acquisitions / Subsidiaries

Company NameDateDeal Size
Theravance Biopharma Antibiotics IP
Theravance Biopharma Ireland Limited
Theravance Biopharma R&D
Theravance Biopharma R&D IP
Theravance Biopharma UK Limited
Theravance Biopharma US
Triple Royalty Sub LLC

Theravance Biopharma Revenue Breakdown

Embed Graph

Theravance Biopharma revenue breakdown by geographic segment: 18.4% from Europe, 81.6% from US and 0.0% from Other

Theravance Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Theravance Biopharma Online and Social Media Presence

Embed Graph

Theravance Biopharma Company Culture

  • Overall Culture

    B-

    75/100

  • CEO Rating

    A

    80/100

  • Compensation

    D

    54/100

Learn more on Comparably

Theravance Biopharma News and Updates

Theravance Biopharma, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ending September 30, 2020. Theravance Biopharma's Total Revenue for the third quarter 2020 was $18.3 million....

Thinking about buying stock in Novan, Energy Focus, Theravance Biopharma, Alphatec, or Jumia Technologies?

NEW YORK, Oct. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOVN, EFOI, TBPH, ATEC, and JMIA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Theravance Biopharma to Report Second Quarter 2020 Financial Results on August 6, 2020

DUBLIN, July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and provide a...

Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directors

DUBLIN, July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the...

Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-0903 for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

DUBLIN and SOUTH SAN FRANCISCO, Calif., June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective...

Theravance Biopharma Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, Feb. 11, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the...
Show more

Theravance Biopharma Blogs

Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference

Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference Content Import Tue, 01/05/2021 - 06:00 Theravance Biopharma To Present at the 39th Annual J.P. Morgan Healthcare Conference January 5, 2021 at 6:00 AM EST This release is a ba…

Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference

DUBLIN , Nov. 17, 2020 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will webcast a presentation as follows:     Evercore ISI 3 rd Annual

Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020

Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 Content Import Thu, 10/22/2020 - 06:00 Theravance Biopharma to Report Third Quarter 2020 Financial Results on November 5, 2020 October 22, 2020 at 6:00 AM EDT This release …

Theravance Biopharma to Present at Upcoming Investor Conferences

Theravance Biopharma to Present at Upcoming Investor Conferences Content Import Tue, 09/01/2020 - 06:00 Theravance Biopharma to Present at Upcoming Investor Conferences September 1, 2020 at 6:00 AM EDT This release is a backfill from a News Wire …

Theravance Biopharma, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update

- Ampreloxetine and TD-1473 programs progressing towards three data readouts in 2021   - YUPELRI® (revefenacin) gained market share despite COVID-19 impact on market demand   - TD-0903 program completed Phase 1, and now enrolling Phase 2   - The Company maintains 2020 financial guidance DUBLIN ,

Deepa R. Pakianathan, Ph.D.

Deepa R. Pakianathan, Ph.D. san.mai@intrado.com Wed, 07/08/2020 - 14:17 Member of the Audit Committee Member of the Science and Technology Committee Deepa R. Pakianathan, Ph.D.
Show more

Theravance Biopharma Frequently Asked Questions

  • When was Theravance Biopharma founded?

    Theravance Biopharma was founded in 1996.

  • Who are Theravance Biopharma key executives?

    Theravance Biopharma's key executives are Rick Winningham, Gary Barrera and Eran Broshy.

  • How many employees does Theravance Biopharma have?

    Theravance Biopharma has 363 employees.

  • What is Theravance Biopharma revenue?

    Latest Theravance Biopharma annual revenue is $60.4 m.

  • What is Theravance Biopharma revenue per employee?

    Latest Theravance Biopharma revenue per employee is $166.3 k.

  • Who are Theravance Biopharma competitors?

    Competitors of Theravance Biopharma include Acceleron Pharma, Inflazome and Prothena.

  • Where is Theravance Biopharma headquarters?

    Theravance Biopharma headquarters is located at Connaught House, 1 Burlington Rd, Dublin.

  • Where are Theravance Biopharma offices?

    Theravance Biopharma has offices in Dublin and San Francisco.

  • How many offices does Theravance Biopharma have?

    Theravance Biopharma has 2 offices.